Roche sets sights on Novartis, Biogen as SMA trial hits target
FILE PHOTO: Roche tablets are seen positioned in front of a displayed Roche logo in this photo illustration January 22, 2016. REUTERS/Dado Ruvic ZURICH (Reuters) – Roche’s bid to rival…
Roche drug for spinal muscular atrophy hits target in late-stage trial
ZURICH (Reuters) – Roche’s bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift on Monday when the Swiss drugmaker said its drug risdiplam improved…